Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6490884

NCCCC(N)=O.O=C(O)C(F)(F)F

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
BLM P54132 3/20 0.50
HDAC6 Q9UBN7 2/20 0.50
THRB P10828 2/20 0.50
KMT2A Q03164 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
GABRR3 A8MPY1 1/20 0.50
GABRP O00591 1/20 0.50
GABRD O14764 1/20 0.50
HDAC3 O15379 1/20 0.50
GABBR2 O75899 1/20 0.50
CYP1A2 P05177 1/20 0.50
GABRA1 P14867 1/20 0.50
TSHR P16473 1/20 0.50
GABRB1 P18505 1/20 0.50
GABRG2 P18507 1/20 0.50
GABRR1 P24046 1/20 0.50
GABRB3 P28472 1/20 0.50
GABRR2 P28476 1/20 0.50
SLC6A1 P30531 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL1930024 0.91 LMNA (0.54) LMNABLMHDAC6THRBKMT2A
Trifluoroacetic Acid SCHEMBL28761253 0.91 LMNA (0.54) LMNABLMHDAC6THRBKMT2A
Trifluoroacetic Acid SCHEMBL3149183 0.88 HRH4 (0.36) LMNABLMHDAC6THRBKMT2A
Trifluoroacetic Acid SCHEMBL30169296 0.87 SLC22A6 (0.38) BLMHDAC6KMT2ACYP1A2HRH4
Trifluoroacetic Acid SCHEMBL30882498 0.87 SLC22A6 (0.38) BLMHDAC6KMT2ACYP1A2HRH4
Gamma-Aminobutyric Acid SCHEMBL9049554 0.86 LMNA (0.71) LMNABLMHDAC6THRBKMT2A
Trifluoroacetic Acid SCHEMBL10619767 0.85 ODC1 (0.48) LMNABLMHDAC6THRBKMT2A
Trifluoroacetic Acid SCHEMBL3149196 0.85 ODC1 (0.48) LMNABLMHDAC6THRBKMT2A
Succinamide SCHEMBL27483865 0.85 ALOX15 (0.39) LMNABLMKMT2ACYP1A2HRH4
Trifluoroacetic Acid SCHEMBL6490887 0.85 HRH4 (0.50) LMNABLMHDAC6THRBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6933296-B2 Compounds effective as β2-adrenoreceptor agonists as well as PDE4-inhibitors ALTANA PHARMA B.V. (NL) 2005-08-23 US disclosed
US-20030195215-A1 Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors ALTANA PHARMA B.V. (NL) 2003-10-16 US disclosed
EP-1296956-A1 COMPOUNDS EFFECTIVE AS BETA-2-ADRENORECEPTOR AGONISTS AS WELL AS PDE4-INHIBITORS ALTANA Pharma AG (DE) 2003-04-02 EP disclosed
WO-2001094319-A1 COMPOUNDS EFFECTIVE AS BETA-2-ADRENORECEPTOR AGONISTS AS WELL AS PDE4-INHIBITORS ALTANA PHARMA AG (DE) 2001-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195215-A1 Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors ADRB1, ADRB2, ADRA1D LMNA 3762/4885BLM 1175/4885HDAC6 1077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.